The latest trading day saw Organon (OGN) settling at $9.05, representing a +1.23% change from its previous close.
Zacks·3d ago
More News
Organon (OGN) Earnings Expected to Grow: Should You Buy?
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks·4d ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·5d ago
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $9.28, marking a -1.07% move from the previous day.
Zacks·9d ago
Organon (OGN) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Organon (OGN) closed at $9.38, indicating a -1.78% shift from the previous trading day.
Zacks·10d ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zacks·10d ago
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·18d ago
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Organon (OGN) reached $10.84 at the closing of the latest trading day, reflecting a -1.54% change compared to its last close.
Zacks·20d ago
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.